October 2024
1. CARTELLA I, Palazzini M, Sirico D, Buono A, et al
   Hypertrophic cardiomyopathy secondary to hydroxychloroquine toxicity in a patient with rheumatoid arthritis.
   Lancet. 2024;404:1560.
   

   >> Share

   
   August 2024
2. FISHER BA, Mariette X, Papas A, Grader-Beck T, et al
   Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
   Lancet. 2024;404:540-553.
   

   >> Share

   
   
3. COLAFRANCESCO S, Priori R
   Sjogren's disease: a new era for clinical trials?
   Lancet. 2024;404:498-499.
   

   >> Share

   
   February 2024
4. VAN DER HELM-VAN MIL AHM
   Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
   Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
   

   >> Share

   
   
5. RECH J, Tascilar K, Hagen M, Kleyer A, et al
   Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
   Lancet. 2024 Feb 13:S0140-6736(23)02650-8. doi: 10.1016/S0140-6736(23)02650.
   

   >> Share

   
   
6. COPE AP, Jasenecova M, Vasconcelos JC, Filer A, et al
   Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
   Lancet. 2024 Feb 13:S0140-6736(23)02649-1. doi: 10.1016/S0140-6736(23)02649.
   

   >> Share

   
   November 2023
7. DI MATTEO A, Bathon JM, Emery P
   Rheumatoid arthritis.
   Lancet. 2023;402:2019-2033.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share